Cytek Biosciences to Report Second Quarter 2022 Financial Results on August 10, 2022
Cytek Biosciences (Nasdaq: CTKB) will report its second quarter 2022 financial results after market close on August 10, 2022. A conference call will follow on the same day at 2:00 p.m. PT to discuss the results and future outlook. Cytek is a leader in cell analysis solutions, known for its Full Spectrum Profiling™ (FSP™) technology, which enhances cell analysis precision and multiplexing capabilities. Its FSP platform includes instruments like Aurora and Northern Lights™ and reagents tailored for research purposes only. For more details, visit their investor relations website.
- Upcoming conference call to discuss second quarter results may provide insights into financial performance and growth metrics.
- Strong focus on advanced cell analysis technology with Full Spectrum Profiling™, potentially attracting research partnerships.
- The need for regulatory approval in various regions may limit product availability and market expansion.
FREMONT, Calif., July 20, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the second quarter 2022 after market close on Wednesday, August 10th, 2022. The company’s management will webcast a corresponding conference call beginning at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its results, business developments and outlook.
Live audio of the webcast will be available on the “Investors” section of the company website at investors.cytekbio.com
About Cytek Biosciences
Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP™) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s FSP platform includes its core instruments, the Aurora and Northern Lights™ systems; its cell sorter, the Aurora CS; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com.
Other than Cytek’s Northern Lights CLC system and certain reagents for use therewith, which are available for clinical use in countries where the regulatory approval has been obtained from the local regulatory authorities, including China and the European Union, Cytek’s products are for research use only and not for use in diagnostic procedures. Please contact your local sales representatives for the status of local regulatory approval.
Cytek, Full Spectrum Profiling, FSP and Northern Lights are trademarks or registered trademarks of Cytek Biosciences, Inc.
In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and corporate Twitter account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek’s website, LinkedIn page, and Twitter account in addition to following its SEC filings, news releases, public conference calls and webcasts.
Investor Relations Contact:
Paul D. Goodson
Head of Investor Relations
pgoodson@cytekbio.com
Media Contact:
Stephanie Olsen
Lages & Associates
(949) 453-8080
stephanie@lages.com
FAQ
When will Cytek Biosciences report its second quarter 2022 financial results?
What time is the conference call for Cytek's Q2 2022 results?
What technology does Cytek utilize for cell analysis?
Where can I listen to the webcast of Cytek's conference call?
What are the core products offered by Cytek Biosciences?
